Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer

Oncogene

Volumn 33, Issue 22, 2014, Pages 2846-2856

  Panupinthu, N ^a,b   Yu, S ^a   Zhang, D ^a   Zhang, F ^a   Gagea, M ^a   Lu, Y ^a   Grandis, J R ^c   Dunn, S E ^d   Lee, H Y ^e   Mills, G B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Mahidol University   (Thailand)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Konyang University   (South Korea)

Author keywords

autoregulation; crosstalk; feedback; G protein coupled receptor; receptor tyrosine kinase

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; Y BOX BINDING PROTEIN 1;

ARTICLE; AUTOREGULATION; CANCER PROGNOSIS; CONTROLLED STUDY; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SELF CONCEPT; TRANSACTIVATION;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROGNOSIS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS PP60(C-SRC); RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; Y-BOX-BINDING PROTEIN 1;

EID: 84901818936     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.259     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30
2. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361: 170-177.
3. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
4. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 2008; 26: 20-25.
5. Jones S, Wang TL, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol 2012; 226: 413-420.
6. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer 1997; 71: 31-34. (Pubitemid 27158406)
7. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1: 1223-1232.
8. Tabchy A, Tigyi G, Mills GB. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. Nat Struct Mol Biol 2011; 18: 117-118.
9. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 2002; 158: 227-233.
10. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582-591. (Pubitemid 37328830)
11. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630-1642.
12. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL et al. YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst 2012; 104: 133-146.
13. Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S et al. Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 2007; 26: 2736-2746. (Pubitemid 46663838)
14. Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H et al. Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 1999; 85: 2450-2454. (Pubitemid 29244855)
15. Yahata H, Kobayashi H, Kamura T, Amada S, Hirakawa T, Kohno K et al. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 2002; 128: 621-626. (Pubitemid 35435560)
16. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 2008; 10: R99.
17. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E et al. Akt phosphor-ylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 2005; 24: 4281-4292. (Pubitemid 40961781)
18. Berquin IM, Pang B, Dziubinski ML, Scott LM, Chen YQ, Nolan GP et al. Y-box-binding protein 1 confers EGF independence to human mammary epithelial cells. Oncogene 2005; 24: 3177-3186. (Pubitemid 40695086)
19. Tothill RW, Tinker AV, George J, Brown R, Fox SB, Lade S et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
20. 2. Clin Cancer Res 2000; 6: 2482-2491. (Pubitemid 30399219)
21. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004; 279: 9653-9661. (Pubitemid 38296034)
22. Fang X, Yu S, Eder A, Mao M, Bast Jr. RC, Boyd D et al. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 1999; 18: 6635-6640.
23. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011; 30: 4567-4577.
24. Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 2012; 11: 720-729.
25. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005; 65: 1027-1034. (Pubitemid 40216465)
26. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 2008; 68: 2366-2374. (Pubitemid 351521811)
27. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemother-apeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010; 9: 1956-1967.
28. Cherrin C, Haskell K, Howell B, Jones R, Leander K, Robinson R et al. An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo. Cancer Biol Ther 2010; 9: 493-503.
29. Ericson K, Gan C, Cheong I, Rago C, Samuels Y, Velculescu VE et al. Genetic inactivation of AKT1, AKT2, and PDPK1 in human colorectal cancer cells clarifies their roles in tumor growth regulation. Proc Natl Acad Sci USA 2010; 107: 2598-2603.
30. Andreev J, Galisteo ML, Kranenburg O, Logan SK, Chiu ES, Okigaki M et al. Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated protein (MAP) kinase signaling cascade. J Biol Chem 2001; 276: 20130-20135.
31. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62: 5749-5754. (Pubitemid 35204731)
32. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
33. Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69: 5851-5859.
34. 2 and receptor transactivation. Am J Physiol Cell Physiol 2010; 298: C163-C170.
35. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, Kon J et al. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 2003; 64: 994-1005. (Pubitemid 37153068)
36. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 1999; 96: 1415-1420. (Pubitemid 29098465)
37. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1- yl)-2-methyl-pyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658-6661. (Pubitemid 40053752)
38. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H et al. Phosphorylation of TNF-a converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA 2006; 103: 6901-6906.
39. Bergmann S, Royer-Pokora B, Fietze E, Jurchott K, Hildebrandt B, Trost D et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 2005; 65: 4078-4087. (Pubitemid 40775644)
40. Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell 2009; 15: 402-415.
41. Jurchott K, Kuban RJ, Krech T, Bluthgen N, Stein U, Walther W et al. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells. PLoS Genet 2010; 6: e1001231.
42. Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J et al. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. Stem Cells 2012; 30: 1338-1348.
43. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 2006; 66: 4872-4879.
44. Berquin IM, Dziubinski ML, Nolan GP, Ethier SP. A functional screen for genes inducing epidermal growth factor autonomy of human mammary epithelial cells confirms the role of amphiregulin. Oncogene 2001; 20: 4019-4028. (Pubitemid 32681607)
45. Normanno N, Selvam MP, Qi CF, Saeki T, Johnson G, Kim N et al. Amphiregulin as an autocrine growth factor for c-Ha-ras-and c-erbB-2-transformed human mammary epithelial cells. Proc Natl Acad Sci USA 1994; 91: 2790-2794.
46. Rodland KD, Bollinger N, Ippolito D, Opresko LK, Coffey RJ, Zangar R et al. Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells. J Biol Chem 2008; 283: 31477-31487.
47. Cook SJ, McCormick F. Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lyso-phosphatidic acid-stimulated DNA synthesis in Rat-1 cells. Biochem J 1996; 320 (Pt 1): 237-245. (Pubitemid 26400186)
48. Boerner JL, Biscardi JS, Silva CM, Parsons SJ. Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005; 44: 262-273. (Pubitemid 41780750)
49. Jeong KJ, Cho KH, Panupinthu N, Kim H, Kang J, Park CG et al. EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: inhibition by resveratrol. Mol Oncol 2013; 7: 121-129.
50. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F et al. A module of negative feedback regulators defines growth factor signaling. Nat Genet 2007; 39: 503-512. (Pubitemid 46514770)
51. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 2010; 102: 941-946.
52. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009; 28: 3801-3813.
53. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 2007; 6: 1414-1424. (Pubitemid 46712005)
54. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L et al. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010; 2010: 568938.
55. Busser B, Sancey L, Josserand V, Niang C, Favrot MC, Coll JL et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther 2010; 18: 528-535.
56. Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K et al. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One 2010; 5: e12661.
57. Zhang L, Wei Q, Mao L, Liu W, Mills GB, Coombes K. Serial dilution curve: a new method for analysis of reverse phase protein array data. Bioinformatics 2009; 25: 650-654.
58. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868. (Pubitemid 29003722)